The peroxisome is a cellular organelle dedicated in part to processing the fatty acids that mitochondria cannot — very long chains (more than 20 carbons), branched-chain fatty acids such as phytanic acid, and the bile acid precursors derived from cholesterol. D-bifunctional protein (DBP), encoded by HSD17B4, performs two sequential steps in this peroxisomal beta-oxidation¹¹ peroxisomal beta-oxidation
The peroxisomal beta-oxidation spiral shortens very long-chain and branched fatty acids by two carbons per cycle, generating acetyl-CoA and passing the shortened chain to mitochondria for complete oxidation. DBP catalyses the second (hydratase) and third (dehydrogenase) reactions of each cycle pathway. When DBP fails, these substrates accumulate to toxic levels in the nervous system, gonads, and other tissues.

The c.715-1G>A variant destroys the canonical splice acceptor site at the boundary of intron 9 and exon 10. This is not a subtle regulatory tweak — it eliminates a signal the spliceosome depends on to excise intron 9 cleanly. The result is aberrant splicing²² aberrant splicing
Splice acceptor variants at the invariant AG dinucleotide of an intron typically cause exon skipping, intron retention, or activation of cryptic splice sites — all of which produce frameshifted or truncated transcripts that are degraded by nonsense-mediated decay or yield a non-functional protein, essentially silencing that copy of HSD17B4.

The Mechanism

The splice acceptor at the 3′ end of an intron is defined by the invariant AG dinucleotide. The c.715-1G>A change replaces the G at position −1 of the intron 9 acceptor — the last nucleotide before the exon begins. This position is part of the [polypyrimidine-tract/AG motif | The spliceosomal U2AF complex recognises the polypyrimidine tract and the invariant AG to position the 3′ splice site. Even a single nucleotide change at the −1G position can completely abolish recognition] that the spliceosome recognises. Disrupting it prevents correct intron removal; the downstream exon is skipped or the intron is retained, and the altered transcript is either degraded by [nonsense-mediated decay | NMD is a cellular surveillance mechanism that degrades mRNAs containing premature stop codons — including those produced by exon skipping with frameshift] or produces a severely truncated, inactive protein. Because DBP is a bifunctional enzyme, loss of either catalytic domain blocks the entire beta-oxidation of very long-chain fatty acids, causing accumulation of C26:0, pristanic acid, and [bile acid intermediates | Di- and trihydroxycholestanoic acid (DHCA and THCA) are intermediates in bile acid synthesis that require peroxisomal oxidation by DBP to become chenodeoxycholic and cholic acid. In DBP deficiency these intermediates accumulate in plasma and urine] in plasma and tissues.

The Evidence

The association of HSD17B4 null alleles with fatal peroxisomal disease has been established across decades of case series and biochemical studies. Ferdinandusse et al. 2006 characterised 110 patients with DBP deficiency, identifying 61 distinct mutations³³ Ferdinandusse et al. 2006 characterised 110 patients with DBP deficiency, identifying 61 distinct mutations
Ferdinandusse et al. Mutational spectrum of D-bifunctional protein deficiency and structure-based genotype-phenotype analysis. Am J Hum Genet. 2006;78(1):112-24. The defining genotype-phenotype rule across this cohort: residual enzyme activity predicts survival. Patients carrying two null alleles (including splice-site variants) showed no detectable DBP activity and the most severe neonatal phenotype — hypotonia, seizures, absent psychomotor development, and death typically within the first two years of life.

The discovery that milder HSD17B4 alleles cause Perrault syndrome rather than neonatal death came from whole-exome sequencing. Pierce et al. 2010 identified the first compound heterozygous HSD17B4 family⁴⁴ Pierce et al. 2010 identified the first compound heterozygous HSD17B4 family
Pierce et al. Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault syndrome. Am J Hum Genet. 2010;87(2):282-288: two sisters with sensorineural hearing loss, primary ovarian insufficiency, and ataxia — none of whom had the catastrophic neonatal course. Their mutations reduced but did not abolish DBP activity. This established that heterozygous carriage of one null allele (like a splice-site variant) paired with one hypomorphic allele produces a survivable but multisystem disorder. A splice-site null paired with a second null allele, by contrast, predicts a severe neonatal presentation.

McMillan et al. 2012 described a fourth clinical subtype (Type IV)⁵⁵ McMillan et al. 2012 described a fourth clinical subtype (Type IV) in two brothers with adult-onset cerebellar ataxia, peripheral neuropathy, and hearing loss — but normal plasma VLCFA levels. Their compound heterozygous mutations each reduced but did not abolish a single catalytic domain, leaving enough combined activity to avoid neonatal disease while producing progressive neurodegeneration in adulthood. This case underscores that negative plasma VLCFA screening does not exclude HSD17B4-deficiency when one allele is a hypomorph.

Werner et al. 2022 (PMID 34623748)⁶⁶ Werner et al. 2022 (PMID 34623748) reported a neonate with two HSD17B4 splice variants confirmed by RNA sequencing to cause exon 14 skipping, documenting virtually absent DBP activity in fibroblasts and an expanded phenotype that included persistent hypoglycemia — a then-novel finding that broadens the clinical spectrum.

Practical Actions

For individuals heterozygous for c.715-1G>A: carrier status is clinically silent but carries a 25% risk of an affected child if a partner also carries a pathogenic HSD17B4 allele. Genetic counselling and partner testing are the actionable steps. Carrier status alone does not cause accumulation of VLCFA or any known biochemical abnormality.

For individuals who are compound heterozygous (one c.715-1G>A allele plus one additional pathogenic allele): the clinical picture depends critically on the second allele's residual activity. Genetic counselling, metabolic specialist referral, and biochemical testing (plasma VLCFA, pristanic acid, bile acid intermediates; fibroblast DBP enzyme assay if plasma is normal) are the cornerstones of diagnosis. No disease-modifying therapies exist; management is supportive.

Interactions

This variant functions as a null allele at the HSD17B4 locus. Its clinical consequences depend entirely on the genotype at the second allele (compound heterozygosity is the rule for affected patients, since homozygous null variants at HSD17B4 are compatible with survival only in the case of residual activity from other mechanisms). Related SNPs already in the GeneOps database include rs137853096 (Gly16Ser, dehydrogenase domain) and rs137853097 (Asn457Tyr, hydratase domain) — both pathogenic missense variants in HSD17B4 that can compound with this splice allele.

Important Limitation: According to 23andMe's own geneticists, rs25531 is not reliably genotyped on consumer platforms¹¹ not reliably genotyped on consumer platforms
David Hinds of 23andMe reported that "nearly everyone (99.97%) is getting called as CC, and there is no clear heterozygote cluster" and "the genotype calls for rs25531 on our platform are not meaningful". This SNP requires specialized genotyping methods. If your 23andMe data shows AA for rs25531, it is likely a technical artifact rather than your true genotype. This article is included for scientific completeness and for users who have obtained clinical genotyping.

The serotonin transporter gene SLC6A4²² serotonin transporter gene SLC6A4
encodes the protein responsible for clearing serotonin from synapses is one of the most studied genes in psychiatry. The well-known 5-HTTLPR insertion/deletion polymorphism in the gene's promoter has been linked to depression, anxiety, and antidepressant response³³ depression, anxiety, and antidepressant response
though results have been inconsistent across studies for decades. But rs25531, a single nucleotide A→G substitution located within the long (L) allele of 5-HTTLPR, adds a critical layer of complexity: it effectively converts an L allele to function like the short (S) allele⁴⁴ it effectively converts an L allele to function like the short (S) allele
when G is present at rs25531, the L allele has transcriptional activity comparable to the S allele rather than high activity.

The Mechanism

The 5-HTTLPR polymorphism consists of a 44-base-pair insertion/deletion in the SLC6A4 promoter region, creating short (S, 14 repeats) and long (L, 16 repeats) variants. Early research suggested the L allele produced 2-3 times more serotonin transporter mRNA than the S allele⁵⁵ Early research suggested the L allele produced 2-3 times more serotonin transporter mRNA than the S allele
Lesch et al. Science, 1996. However, rs25531 revealed that not all L alleles are functionally equivalent⁶⁶ rs25531 revealed that not all L alleles are functionally equivalent
Hu et al. identified that an A→G substitution at rs25531 within the L allele creates a binding site for the AP-2 transcription factor.

The result is a triallelic system: L_A (L allele with A at rs25531) has high transporter expression, while L_G (L allele with G at rs25531) has low expression similar to the S allele⁷⁷ L_G (L allele with G at rs25531) has low expression similar to the S allele
the G variant disrupts transcription factor binding, reducing promoter activity. This creates a functional hierarchy: L_AL_A > L_AS > L_AL_G > L_GL_G ≈ L_GS > SS in terms of serotonin transporter expression.

The Evidence

The G allele frequency varies dramatically by ancestry⁸⁸ The G allele frequency varies dramatically by ancestry
European-Americans: 7.5%, African-Americans: 21%, reflecting significant population stratification. In the largest study to date of 954 African-American and 2,622 European-American subjects⁹⁹ the largest study to date of 954 African-American and 2,622 European-American subjects
Odgerel et al. Translational Psychiatry, 2013, the G allele was nearly three times more common in African-Americans, and when 5-HTTLPR and rs25531 were combined into high- and low-transcription haplotypes, African-Americans showed significantly fewer low-transcription variants overall.

The clinical significance remains controversial and inconsistent¹⁰¹⁰ controversial and inconsistent
multiple meta-analyses have produced conflicting results. Some studies suggest that individuals with L_AL_A genotypes respond better to SSRIs¹¹¹¹ individuals with L_AL_A genotypes respond better to SSRIs
particularly in Caucasian populations, though effect sizes are modest, while others find no association between rs25531 and treatment outcome¹²¹² no association between rs25531 and treatment outcome
four large studies including STAR*D analyses found no predictive value.

One study found that SSRI serum concentrations correlated with response only in L_A carriers¹³¹³ One study found that SSRI serum concentrations correlated with response only in L_A carriers
suggesting dose-dependent effects specific to the high-expression genotype. Intriguingly, rs25531 also influences opioid analgesia¹⁴¹⁴ rs25531 also influences opioid analgesia
individuals with low-expression genotypes (SA/SA or SA/L_G) showed significantly better pain relief from remifentanil than L_AL_A individuals, suggesting the variant affects multiple neurotransmitter-related drug responses.

Practical Implications

The primary clinical question is whether rs25531 genotyping improves antidepressant selection beyond 5-HTTLPR alone. Current evidence suggests limited additional predictive value¹⁵¹⁵ Current evidence suggests limited additional predictive value
CPIC does not include rs25531 in its recommendations, and multiple studies found no added specificity. The GeneSight pharmacogenomic test¹⁶¹⁶ GeneSight pharmacogenomic test
a commercial panel for antidepressant selection notes that "more data is needed before the rs25531 SNP can be recommended for use in treatment selection."

However, for individuals with clinically obtained rs25531 genotyping, there are some tentative guidelines: Those with G alleles may experience more side effects from SSRIs¹⁷¹⁷ G alleles may experience more side effects from SSRIs
particularly gastrointestinal symptoms and headaches and may benefit from starting at lower doses or considering non-SSRI alternatives. Medications like mirtazapine, which has minimal serotonin transporter affinity¹⁸¹⁸ Medications like mirtazapine, which has minimal serotonin transporter affinity
showed no impact or even improved response in low-expression genotypes, making them reasonable alternatives.

Interactions

Rs25531 must be interpreted together with 5-HTTLPR, as they are in tight linkage disequilibrium and the G allele is almost always found on the L allele background¹⁹¹⁹ the G allele is almost always found on the L allele background
rarely occurring with the S allele. The triallelic classification (L_A, L_G, S) provides more accurate functional prediction than the biallelic (L, S) system alone. Other SLC6A4 polymorphisms including rs2020933 and STin2²⁰²⁰ Other SLC6A4 polymorphisms including rs2020933 and STin2
also affect transporter expression and may compound with rs25531, though the clinical utility of multi-variant haplotypes remains uncertain.

Gene-environment interactions are also critical²¹²¹ Gene-environment interactions are also critical
the combination of low-expression genotypes and stressful life events appears to increase depression risk more than either factor alone, though this finding has been challenged by large meta-analyses. Epigenetic modifications including DNA methylation of the SLC6A4 promoter²²²² Epigenetic modifications including DNA methylation of the SLC6A4 promoter
may interact with rs25531 genotype to affect both expression and treatment response.

Familial Mediterranean fever (FMF) is the most common hereditary autoinflammatory disease, driven by gain-of-function variants in MEFV that destabilize pyrin's normally tight control over the inflammasome. Pyrin¹¹ Pyrin
a 781-amino acid protein expressed in neutrophils, monocytes, and dendritic cells that assembles the pyrin inflammasome and controls caspase-1-mediated IL-1β release; named for the Greek word for fever operates as a conditional alarm sensor — active only when genuine pathogen-derived toxins disable the regulatory Rho GTPase pathway. FMF mutations lower this threshold, triggering unprovoked IL-1β storms that manifest as self-limiting 12–72 hour attacks of fever and serositis. M680I is one of five founder mutations²² founder mutations
mutations that arose in a common ancestral population and persisted as carrier groups migrated across the Mediterranean and Middle East; the five account for ~74% of FMF chromosomes in Armenians, Arabs, Jews, and Turks that collectively define the FMF mutation spectrum.

M680I (c.2040G>C on the coding strand, p.Met680Ile) sits in exon 10 at codon 680 — one of two severity hotspots in pyrin's B30.2 regulatory domain. Touitou (2001)³³ Touitou (2001) described codons 680 and 694 as the "mutational hot-spots" of the gene and found that genotypes combining two mutations within these codons are consistently associated with severe phenotypes. ClinVar classifies all three c.2040G> nucleotide variants (G>C, G>A, G>T) as Pathogenic or Pathogenic/Likely pathogenic across independent submissions, with no conflicts.

The Mechanism

Met680 lies within the B30.2 (SPRY) domain⁴⁴ B30.2 (SPRY) domain
the C-terminal regulatory domain of pyrin that senses effectors of the RhoA GTPase signaling axis; when the Rho pathway is disrupted by bacterial toxins, B30.2 detects this and licenses inflammasome assembly of pyrin, at a position closely adjacent to the codon 694 hotspot occupied by M694V and M694I. In the resting state, the regulatory kinases PKN1 and PKN2 phosphorylate pyrin at S208 and S242, and the 14-3-3 proteins bind to hold the inflammasome inactive. Substituting the bulky, flexible methionine at position 680 with the branched-chain isoleucine alters the local conformation of the B30.2 domain, disrupting the PKN1/14-3-3 regulatory contact. The result is partial constitutive inflammasome activation: caspase-1 cleaves pro-IL-1β and pro-IL-18 without the microbial trigger normally required, producing episodes of sterile inflammation in serosal and joint tissues.

The severity of the M680I dysfunction — while unambiguously pathogenic — is intermediate. Being at codon 680 rather than 694 produces a slightly different disruption geometry than M694V, explaining why M680I homozygotes may have a moderately different colchicine responsiveness profile than M694V homozygotes. However, when M680I is combined with M694V on the opposite chromosome, the compound heterozygous phenotype approaches the severity of M694V homozygosity.

The Evidence

M680I is the second most commonly identified MEFV disease allele in large FMF cohorts. In the largest published pediatric FMF registry — Öztürk et al. 2022⁵⁵ Öztürk et al. 2022, n=3,454 patients — M680I accounted for 11.3% of all disease alleles, compared to 55.3% for M694V and 7.6% for V726A. Exon 10 mutation carriers as a group had earlier disease onset (4.6 vs. 5.6 years for exon 2 carriers) and more frequent attacks. Population genetics meta-analysis (Papadopoulos et al. 2008⁶⁶ Papadopoulos et al. 2008, cumulative dataset) confirmed M680I at 11.4% of disease alleles across Mediterranean populations, with the mutation enriched primarily in Armenian and Turkish founder groups.

The severity framework for M680I is grounded in the codon-hotspot principle. Touitou (2001) established that genotypes combining two mutations at codons 680 and/or 694 reliably produce severe disease. A systematic review by Gangemi et al. 2018⁷⁷ Gangemi et al. 2018 — covering over 280 MEFV variants — confirmed that M680I homozygotes and M680I/M694 compound heterozygotes have severe disease presentations, though precise quantitative severity scores for isolated M680I homozygosity are less thoroughly characterized in the literature than for M694V, reflecting that homozygous M680I patients are outnumbered by M694V homozygotes in most published cohorts (e.g., 3 vs. 7 homozygotes in one Egyptian registry of 426 patients, Al-Haggar et al. 2014⁸⁸ Al-Haggar et al. 2014).

Compound heterozygosity with M694V is the most clinically critical M680I configuration. Barut et al. 2018⁹⁹ Barut et al. 2018 documented that pediatric amyloidosis cases arose in M694V homozygotes and M694V/M680I compound heterozygotes — placing M680I in the same high-risk amyloidosis tier as M694V when combined with a second high-severity allele. Caglayan et al. 2010¹⁰¹⁰ Caglayan et al. 2010 found M680I in 14.5% of disease alleles in their compound heterozygous FMF cohort; overall colchicine effectiveness was 83% regardless of mutation type, suggesting M680I compound heterozygotes are generally colchicine-responsive, though a subset requiring IL-1 inhibitors is enriched for M694V/M680I genotypes.

Practical Implications

For heterozygous carriers of M680I without clinical FMF symptoms, no colchicine treatment is warranted. FMF is autosomal recessive; a single M680I allele is generally insufficient for full-expression disease, though subclinical inflammatory marker elevation has been documented in obligate heterozygotes across the MEFV hotspot mutations. The clinically urgent scenario is the undiagnosed compound heterozygote: a person carrying M680I on one chromosome and M694V (or another pathogenic allele) on the other may develop clinically significant FMF requiring colchicine — and will be missed by single-site testing.

For confirmed FMF patients (homozygous M680I or compound heterozygous), colchicine at 1.0–2.0 mg/day is the standard prophylactic therapy. The target is complete attack suppression AND normalization of inter-attack serum amyloid A (SAA) — the latter is critical because sustained subclinical elevation of SAA drives the reactive AA amyloidosis that historically caused renal failure and death in inadequately treated FMF. Colchicine is highly effective in the majority of M680I patients; the subset with persistent attacks on ≥2 mg/day should be evaluated for IL-1 inhibitor therapy (anakinra or canakinumab).

Periodic urinalysis for proteinuria (every 6 months) is recommended as an early screen for renal AA amyloidosis, per EULAR FMF management guidelines, in all confirmed pathogenic MEFV genotypes.

Interactions

M680I's most clinically important interaction is compound heterozygosity with M694V (rs61752717). The M694V/M680I compound genotype elevates disease severity above what either allele alone might predict in heterozygosity, approaching the severe tier associated with M694V homozygosity. These patients tend to have higher colchicine requirements and are among those most likely to require IL-1 inhibitor escalation.

M680I can also form a compound genotype with V726A (rs28940579). The V726A/M680I combination appears in Arab and Turkish cohorts and produces a moderate phenotype — more active than V726A homozygosity but less severe than M694V-containing compound genotypes. Compared with M694V/M680I, V726A/M680I disease course is more manageable on standard colchicine doses.

For any M680I heterozygote presenting with FMF-like symptoms, a comprehensive MEFV panel covering all common exon 10 mutations (M694V, M694I, V726A) and E148Q (rs3743930) is the necessary next step before concluding that M680I heterozygosity alone explains the phenotype.

Inside every vascular endothelial cell and platelet-producing megakaryocyte, a molecular sorting system routes proteins to exactly where they need to go. SNX24 — sorting nexin 24¹¹ SNX24 — sorting nexin 24
a member of the PX-domain sorting nexin family; binds phosphoinositide lipids on endosomal membranes and guides cargo vesicles through the intracellular trafficking network — is one component of this system, specifically required for building platelet alpha-granules and regulating endothelial cytokine output. The rs30021 variant lies deep within the SNX24 gene (c.249+4040G>A), in a non-coding intron region that may influence how much SNX24 is produced in vascular tissues.

While rs30021 itself has not been the direct subject of a published clinical trial, it sits in a biologically rich locus. SNX24's documented roles — controlling von Willebrand factor (VWF) release from platelets and modulating the endothelial inflammatory response — are directly relevant to cardiovascular and venous disease. The G allele of rs30021 is uncommon globally (~23% allele frequency), with marked variation across ancestries: European populations carry it at ~31%, East Asian populations at just ~1%.

The Mechanism

SNX24 acts in the alpha-granule maturation pathway²² alpha-granule maturation pathway
alpha-granules are the most abundant organelle in platelets, storing key hemostatic proteins including VWF, P-selectin, fibrinogen, and platelet factor 4 of megakaryocytes — the bone marrow precursor cells that produce platelets. When SNX24 is knocked out experimentally, megakaryocytes accumulate empty membrane vesicles, fail to form mature multivesicular bodies, and produce platelets that are severely depleted in alpha-granule cargo including VWF and CD62P (P-selectin). These proteins are critical for the initial steps of hemostasis and thrombus formation at sites of vascular injury.

In endothelial cells, SNX24 plays a second, independent role: modulating the inflammatory cytokine response to bacterial lipopolysaccharide. When SNX24 expression is suppressed, endothelial cells produce significantly less IL-1β, IL-6, and IL-8 in response to inflammatory signals. This positions SNX24 as a regulator of endothelial activation — the cellular process that initiates leukocyte recruitment, promotes coagulation, and drives the vascular inflammatory response underlying atherosclerosis and venous wall remodeling.

The rs30021 intronic variant (c.249+4040G>A) does not change the SNX24 protein sequence directly. Deeply intronic variants can influence gene expression through effects on splicing enhancers, intronic regulatory elements, or chromatin accessibility. Whether rs30021 affects SNX24 expression in endothelial or megakaryocyte lineages has not been characterized experimentally.

The Evidence

The direct evidence for rs30021 is limited: no published GWAS hit, no ClinVar entry, and no primary study investigating its phenotypic consequence. It appears in the related-variant set of the VEGFA/5q region varicose vein GWAS context, identified in Ahmed et al. 2022³³ Ahmed et al. 2022
two-stage analysis across 810,000 participants identifying 49 genome-wide significant varicose vein loci.

The biological evidence for SNX24's vascular role is stronger. Lacey et al. 2022⁴⁴ Lacey et al. 2022
CRISPR-Cas9 knockout in iPSC-derived megakaryocytes; n=3 cell lines per condition demonstrated that SNX24 loss eliminates alpha-granule maturation, with direct measurement of VWF reduction — a key coagulation factor also implicated in venous thromboembolism. A separate genetic study Lin et al. 2013⁵⁵ Lin et al. 2013
262 Kawasaki disease patients, 76 with coronary artery aneurysm showed that SNX24 variant rs28891 (a different coding variant in the same gene) associates with coronary artery aneurysm severity, and that endothelial cells with reduced SNX24 expression produce less IL-1β, IL-6, and IL-8 — directly connecting SNX24 function to vascular inflammation.

Given the indirect nature of evidence for rs30021 specifically, this SNP is rated emerging. The classification may be upgraded if eQTL studies confirm that rs30021-G reduces SNX24 expression in vascular or platelet precursor tissues.

Practical Actions

For G allele carriers, the theoretical concern is reduced SNX24 expression in two cell types: megakaryocytes (platelets) and endothelial cells. Reduced SNX24 in megakaryocytes could impair alpha-granule loading, affecting VWF release and platelet adhesion capacity at vascular injury sites. Reduced SNX24 in endothelium could reduce inflammatory cytokine output — a potentially protective effect that makes the directionality of this variant complex.

Monitoring VWF levels (including VWF antigen and activity) can capture downstream effects of platelet alpha-granule dysfunction. VWF Ag below 50% is defined as von Willebrand disease type 1, though this is generally driven by VWF gene variants; moderately low VWF activity (50–100%) influences both bleeding tendency and, paradoxically, cardiovascular risk stratification.

Interactions

rs30021 is listed as a co-variant alongside rs11967262 — a VEGFA upstream regulatory variant strongly associated with varicose veins through the 6p21.1 locus. The co-listing reflects their co-occurrence in varicose vein genetic research rather than physical LD (they are on different chromosomes: rs30021 on chr5, rs11967262 on chr6). Their functional connection is through the shared biological theme of vascular wall integrity and endothelial growth factor signaling.

Another SNX24 variant, rs28891, was specifically associated with coronary artery aneurysm risk in Kawasaki disease. Individuals carrying rs30021-G who also have other variants affecting VWF production (VWF gene variants) or platelet function may have compound effects on hemostasis worth discussing with a hematologist.

The IL2RA locus¹¹ IL2RA locus
IL2RA on chromosome 10p15.1 encodes CD25, the alpha subunit of the high-affinity interleukin-2 receptor, essential for Treg development and maintenance is one of the most replicated non-HLA autoimmune susceptibility regions in the human genome. While rs2104286 is the most commonly cited variant at this locus, fine-mapping studies have established that multiple independent genetic signals coexist in the same region, each tagging distinct regulatory effects on IL-2 receptor expression and immune tolerance. rs3134883 is one of these independent signals — it anchors a five-variant haplotype block with its own disease associations and its own relationship to soluble IL-2 receptor biology.

The Mechanism

rs3134883 sits in an intron of IL2RA at chromosome 10, position 6,058,762 (GRCh38). The IL2RA gene lies on the minus strand, but the variant is always reported in plus-strand notation (G/A) as per the GRCh38 reference. It is not a coding change; rather, it is an intronic tag SNP²² intronic tag SNP
Intronic variants can influence gene expression through effects on transcription factor binding, RNA splicing, chromatin accessibility, or enhancer activity within introns that marks a haplotype block in strong linkage disequilibrium with functional regulatory elements.

The five-variant protective haplotype H5 — comprising rs3134883 (G allele), rs3118470, rs7072793, rs4749955, and rs12251307 — tags a protective IL2RA regulatory state³³ tags a protective IL2RA regulatory state
The H5 haplotype was in perfect LD (r²=1.0) with the minor allele of ss52580101 in CEU populations, a variant associated with altered IL-2RA expression and soluble receptor shedding. The G allele at rs3134883 is the protective allele: carriers of the G-containing haplotype have lower autoimmune disease risk. Conversely, the A allele tags a haplotype block associated with altered IL-2 receptor biology — specifically, with changes to the balance between membrane-bound and soluble IL-2RA that reduce effective IL-2 signaling to regulatory T cells.

Mechanistically, impaired IL-2 signaling through the high-affinity receptor complex (CD25/IL-2Rβ/γc) reduces STAT5 phosphorylation⁴⁴ reduces STAT5 phosphorylation
pSTAT5 is the master downstream signal in Tregs; its reduction impairs FoxP3 expression and Treg suppressive capacity in CD4+CD25+ regulatory T cells, lowering their suppressive capacity. A study in genotype-selected healthy donors confirmed that susceptible IL2RA haplotypes reduce IL-2 responsiveness⁵⁵ susceptible IL2RA haplotypes reduce IL-2 responsiveness
Cerosaletti et al. measured lower pSTAT5a and reduced FOXP3 expression in susceptibility-haplotype carriers versus protective-haplotype carriers and reduce FoxP3 expression, directly linking locus-level genetic variation to Treg function.

The Evidence

The Type I Diabetes Genetics Consortium study⁶⁶ Type I Diabetes Genetics Consortium study
5,003 T1D-affected sib-pair families from a large international consortium, 69 SNPs spanning ~88 kb of IL2RA established rs3134883's place in the IL2RA haplotype architecture. The protective H5 haplotype carrying the G allele showed OR 0.699 (95% CI 0.602–0.811, p=3.2×10⁻⁵) for T1D protection. Crucially, rs3134883 retained independent statistical significance (p=4.29×10⁻³) after conditioning on the full H5 haplotype, suggesting it tags both haplotype-level and potentially position-specific regulatory effects.

For rheumatoid arthritis, rs3134883 is among the lead variants at the IL2RA locus in large-scale GWAS. A multi-ancestry RA GWAS⁷⁷ multi-ancestry RA GWAS
Ishigaki et al. meta-analysis across European and East Asian populations, confirming multiple independent IL2RA signals with OR ~1.1 per A allele at rs3134883 confirmed the A allele at rs3134883 reaches genome-wide significance (p as low as 2×10⁻¹⁵ in the Ha et al. 2020 analysis) with OR approximately 1.1 per allele for seropositive RA. This effect is independent from rs2104286, reflecting the well-established multi-signal architecture⁸⁸ multi-signal architecture
Fine-mapping of IL2RA identifies at least three independent association signals affecting T1D and MS through different molecular pathways of the IL2RA locus.

In vitiligo, a GWAS of Chinese Han participants⁹⁹ GWAS of Chinese Han participants
6,857 vitiligo cases and 12,025 controls in a two-stage replication study confirmed the 10p15.1 locus — encompassing rs3134883 — as a susceptibility locus (OR 1.11, p=1.01×10⁻⁵), demonstrating that the IL2RA risk haplotype extends beyond European-ancestry autoimmune diseases. Lymphocyte count modulation by rs3134883 has also been reported in GWAS (p=2×10⁻²¹), consistent with the locus's role in regulating the size and activation state of T-cell populations.

Practical Implications

The A allele at rs3134883 marks a modest but independently established increase in autoimmune disease susceptibility across multiple diseases — RA, T1D, and vitiligo. Its effect is additive: AA homozygotes carry approximately twice the incremental risk of a single A allele. Because this variant reflects impaired IL-2-driven Treg signaling, the same compensatory strategies relevant to rs2104286 apply here: strategies that shore up Treg function through IL-2-independent pathways.

Vitamin D is particularly relevant because 1,25-dihydroxyvitamin D3 promotes Treg differentiation through the VDR/TGF-β1 pathway independently of IL-2 signaling. Clinical evidence¹⁰¹⁰ Clinical evidence
Prietl et al. demonstrated that vitamin D supplementation increases Treg percentages in healthy subjects through the VDR/PLC-γ1/TGF-β1 axis confirms this pathway directly increases FoxP3+ Treg numbers and function, directly addressing the Treg deficit caused by impaired IL-2 signaling.

For RA specifically, knowledge of IL2RA genotype has implications for treatment response monitoring. IL2RA variation influences lymphocyte counts and immune activation set-points, potentially affecting responsiveness to biologics targeting the TNF or IL-6 pathways. Carriers of the A allele should be attentive to early joint symptoms (morning stiffness, bilateral symmetric joint pain) that may signal early RA before structural damage develops.

Interactions

rs3134883 operates in the same IL2RA locus as rs2104286 and rs2256774, but fine-mapping studies¹¹¹¹ fine-mapping studies
Todd et al. and subsequent work confirm at least three independent signals at IL2RA, with distinct effects on sIL-2RA production, surface CD25 expression, and downstream T-cell signaling establish these as distinct signals with partially non-overlapping effects. Carrying risk alleles at multiple IL2RA variants likely compounds Treg signaling impairment beyond what any single variant predicts. Interactions with CTLA4 rs3087243 (immune checkpoint) and PTPN22 rs2476601 (T-cell activation threshold) are biologically plausible as parallel pathways to Treg and effector T-cell dysregulation.

The MYBPC3 gene encodes cardiac myosin-binding protein C (cMyBP-C)¹¹ cardiac myosin-binding protein C (cMyBP-C)
a thick-filament regulatory protein that modulates the interaction between myosin and actin during each heartbeat. Functioning like a molecular brake on sarcomeric contraction, cMyBP-C is also phosphorylated in response to beta-adrenergic stimulation, allowing the heart to increase its output during exertion. Pathogenic variants in MYBPC3 are the single most common identified cause of hypertrophic cardiomyopathy (HCM)²² hypertrophic cardiomyopathy (HCM)
abnormal thickening of the heart muscle, particularly the interventricular septum, causing impaired filling and obstruction of blood flow, accounting for 40–50% of all genetically solved HCM cases.

The rs36211723 variant substitutes cytosine for thymine at position 2308 of the coding sequence — on the plus (genomic) strand, C is replaced by T at chromosome 11:47338520. Because MYBPC3 is transcribed from the minus strand, this plus-strand C>T change corresponds to a coding-strand G>A transition at the last nucleotide of exon 23, written as c.2308G>A. The resulting amino acid change, p.Asp770Asn, is classified as pathogenic by 18 of 23 ClinVar submitters, with no conflicts.

The Mechanism

What makes rs36211723 unusual is that the pathogenic effect operates through splicing disruption rather than direct protein dysfunction³³ splicing disruption rather than direct protein dysfunction
the substitution falls at the final base of exon 23, a position critical for the exon-intron splice donor signal. Multiple in silico tools predicted elimination of the splice donor site, and experimental confirmation came from RNA analysis of cardiac tissue from patients carrying the variant. RT-PCR of MYBPC3 transcripts from Asp770Asn carriers⁴⁴ RT-PCR of MYBPC3 transcripts from Asp770Asn carriers
reverse-transcriptase PCR amplifying across exons 22–24 detected only wild-type sequence — the mutant mRNA was completely absent, indicating that aberrant splicing leads to nonsense-mediated decay (NMD)⁵⁵ nonsense-mediated decay (NMD)
a cellular quality-control pathway that degrades mRNAs containing premature stop codons or aberrant splice products.

The consequence is haploinsufficiency⁶⁶ haploinsufficiency
the single functional copy of the gene produces insufficient protein to maintain normal sarcomere architecture. Human myectomy studies confirmed that MYBPC3 protein levels are measurably reduced in HCM patient cardiac tissue — approximately 24% below donor controls (p<0.0005) — with no detectable truncated peptides, ruling out a dominant-negative mechanism. Reduced cMyBP-C alters myosin cross-bridge kinetics, shifting the sarcomere toward a hypercontractile state that drives pathological concentric hypertrophy and diastolic dysfunction over time.

The Evidence

ClinVar documents 18 independent submitters classifying rs36211723 as pathogenic, with the variant reported in more than 15 unrelated individuals with HCM and segregating with disease in at least one family. The variant has also been associated with left ventricular noncompaction cardiomyopathy⁷⁷ left ventricular noncompaction cardiomyopathy
a congenital myocardial disorder where the inner layers of the heart fail to compact properly, suggesting MYBPC3 haploinsufficiency can manifest across a spectrum of structural phenotypes.

MYBPC3-related HCM is characterised by incomplete, age-dependent penetrance⁸⁸ incomplete, age-dependent penetrance
not all variant carriers develop detectable HCM in their lifetime, and those who do often present late. Echocardiographic penetrance in carriers under 50 years is approximately 40–65%; this rises to 70–100% in carriers over 55. Cardiac MRI improves detection to 87.2% even in echocardiographically negative carriers. Women with MYBPC3 mutations develop phenotypic HCM approximately 6–13 years later than men on average, though once affected they show worse prognosis.

Carriers of pathogenic MYBPC3 variants face a twofold greater risk of adverse cardiac outcomes and a fourfold higher risk of ventricular arrhythmias compared to HCM patients without identifiable sarcomere mutations, according to Sarcomeric Human Cardiomyopathy Registry data. Sudden cardiac death risk is elevated, particularly in individuals with high-risk features on imaging⁹⁹ high-risk features on imaging
maximal wall thickness ≥30 mm, left ventricular outflow tract obstruction, late gadolinium enhancement on MRI, or family history of SCD.

Practical Actions

Carriers identified genetically but without clinical HCM (genotype-positive, phenotype-negative) require structured cardiac surveillance. The 2024 AHA/ACC HCM guidelines recommend ECG and cardiac imaging every 3–5 years for adult G+/P− carriers. For adolescent carriers (ages 10–20), ESC guidelines recommend annual monitoring given the higher rate of phenotypic conversion in that window.

If HCM is confirmed, management is guided by symptom burden and obstruction severity. Mavacamten — the first FDA-approved cardiac myosin inhibitor — is now a guideline-directed option for symptomatic obstructive HCM, directly targeting the sarcomeric hypercontractility caused by cMyBP-C haploinsufficiency. Beta-blockers and non-dihydropyridine calcium-channel blockers remain first-line for symptom management.

First-degree relatives (parents, siblings, children) of rs36211723 carriers have a 50% probability of inheriting the variant. Cascade genetic testing followed by structured cardiac surveillance is recommended for all at-risk relatives. Clinical-grade confirmatory testing is essential before acting on any consumer or research genotyping result for this variant.

Interactions

MYBPC3 Asp770Asn operates through haploinsufficiency — a single pathogenic copy is sufficient for disease risk. Compound heterozygosity (two MYBPC3 pathogenic variants in trans) produces far more severe, often neonatal-onset cardiomyopathy. If a carrier has a child with another MYBPC3 carrier, that child has a 25% chance of inheriting two pathogenic copies, substantially increasing severity risk.

Variants in other sarcomere genes — particularly MYH7 (rs121913629, beta-myosin heavy chain), TNNT2 (cardiac troponin T), and TNNI3 (cardiac troponin I) — can compound MYBPC3-mediated HCM risk when co-inherited. However, quantified combined-genotype risk estimates for rs36211723 specifically with other sarcomere variants are not yet published.

The MMAB gene encodes ATP:cob(I)alamin adenosyltransferase (ATR)¹¹ ATP:cob(I)alamin adenosyltransferase (ATR)
The enzyme that attaches an adenosyl group to reduced cobalamin, converting it into adenosylcobalamin — the active B12 cofactor required by methylmalonyl-CoA mutase in the mitochondria, the final enzyme in the pathway that converts dietary vitamin B12 into its active mitochondrial form, adenosylcobalamin (AdoCbl). Without AdoCbl, methylmalonyl-CoA mutase²² methylmalonyl-CoA mutase
The mitochondrial enzyme that converts methylmalonyl-CoA to succinyl-CoA; it cannot function without its AdoCbl cofactor, causing methylmalonate to accumulate stalls, causing toxic accumulation of methylmalonate and propionate in blood and tissues. This SNP — rs369296618, c.700C>T, p.Gln234Ter — introduces a premature stop codon at amino acid 234 of the 250-amino-acid MMAB protein. Because it falls in the final (terminal) exon, the truncated transcript may partly escape nonsense-mediated decay (NMD)³³ nonsense-mediated decay (NMD)
A cellular surveillance mechanism that degrades mRNAs with premature stop codons more than ~50 nucleotides upstream of the final exon junction; terminal-exon stop codons often escape, producing a truncated but partially functional protein, leaving behind a shortened protein with residual enzymatic activity in some carriers.

The Mechanism

ATR is a homotrimer that catalyses the final adenosylation step: cob(I)alamin + ATP → adenosylcobalamin + pyrophosphate. The Q234* truncation removes 16 amino acids from the C-terminus of the protein. Because the stop codon is within the terminal exon, the abnormal mRNA may not be fully degraded by NMD, producing some truncated ATR protein. This distinguishes Q234* from early-truncating alleles (e.g., p.Arg186Trp affects the active-site core) — the terminal location preserves some structural integrity, which is why a subset of biallelic Q234* individuals retain partial B12 responsiveness. Forny et al. 2022⁴⁴ Forny et al. 2022
Human Genetics; 97 individuals with bi-allelic MMAB variants confirmed c.700C>T as the most frequent truncating MMAB allele, appearing in 14 patients across the cohort. Disease onset in biallelic carriers ranged from 2 days to 6.5 years of age, reflecting the partial residual activity conferred by terminal-exon escape from NMD.

The Evidence

Manoli et al. (GeneReviews, updated 2022)⁵⁵ Manoli et al. (GeneReviews, updated 2022)
Isolated Methylmalonic Acidemia documents that MMAB variants cause cblB-type methylmalonic aciduria (MMA), accounting for approximately 12% of all isolated MMA cases. The condition follows strict autosomal recessive inheritance — biallelic loss of MMAB function causes accumulation of methylmalonic acid in plasma and urine, with clinical presentations ranging from neonatal hyperammonemic crisis to late-onset renal and neurological complications. Heterozygous carriers are clinically silent and do not require treatment.

ClinVar (VCV000203820) classifies rs369296618 as Pathogenic with two-star review status ("criteria provided, multiple submitters, no conflicts"), supported by eight independent laboratory submissions including Baylor Genetics, Natera, and Victorian Clinical Genetics Services, all confirming the variant in affected individuals in homozygous or compound heterozygous states.

For biallelic disease: hydroxocobalamin therapy (1 mg IM, 1–3 × weekly) is the first-line intervention for B12-responsive cases, alongside dietary protein restriction targeting propiogenic amino acids and supplemental L-carnitine (50–100 mg/kg/day) to maintain plasma carnitine levels and facilitate excretion of propionylcarnitine.

Practical Actions

Heterozygous carriers (AG genotype, ~1 in 2,500 Europeans) have one functional MMAB copy and produce sufficient AdoCbl — no dietary or supplement intervention is needed for the carrier themselves. The clinical relevance is reproductive: if both reproductive partners carry a pathogenic MMAB allele, each pregnancy carries a 25% chance of producing a biallelic child with cblB-type MMA. Newborn screening (tandem mass spectrometry for elevated propionylcarnitine) identifies affected neonates before the first metabolic crisis.

Homozygous AA (effectively impossible in the general population given q ≈ 0.00018) or compound heterozygous states (one copy of this allele + one copy of a different MMAB pathogenic variant such as rs199971687) cause clinical MMA. Management is specialist-led: high-dose hydroxocobalamin, protein restriction, and carnitine supplementation.

Interactions

Compound heterozygosity between rs369296618 and other pathogenic MMAB alleles (particularly rs199971687, a splice-acceptor variant) causes cblB-type MMA with the same clinical spectrum as biallelic state. The Q234* allele specifically may retain partial enzymatic activity, meaning compound heterozygotes carrying Q234* on one allele may show better hydroxocobalamin responsiveness than those with two early-truncating variants. This interaction is well-established in the cblB literature and should inform counselling when both MMAB variants are identified in a couple.

Toll-like receptor 8 (TLR8) is an endosomal sentinel of the innate immune system that detects single-stranded RNA from invading pathogens — including RNA viruses and the RNA-rich debris shed by mycobacteria such as Mycobacterium tuberculosis. TLR8¹¹ TLR8
Toll-like receptor 8, located on chromosome X at Xp22.2, expressed predominantly in monocytes, dendritic cells, and lung tissue sits inside the membranes of intracellular vesicles where it scans the contents of phagocytosed material for pathogen signatures. When activated, it triggers NF-κB and interferon signaling cascades that orchestrate the early inflammatory response. The A1G variant (rs3764880) sits at the very beginning of the TLR8 gene — at the initiator codon — and alters how the cell translates two different versions of the TLR8 protein. Because TLR8 is on the X chromosome, men carry only one copy of this gene, while women carry two. This dosage asymmetry is the key to understanding why the same variant can be protective in one sex and a risk factor in the other.

The Mechanism

The TLR8 gene produces two protein isoforms — TLR8v1 (the shorter form, associated with positive regulation of TLR8 signaling in differentiated monocytes) and TLR8v2 (the predominant form in most immune cells). The A1G variant substitutes a guanine (G) for the adenine (A) at the very first position of the coding sequence, changing the methionine start codon to valine (p.Met1Val) in TLR8v2. A 2010 functional study²² A 2010 functional study
Gantier et al. Immunology and Cell Biology, PMID 20652908 showed that this does not abolish TLR8 protein production but instead shifts the relative translation ratio between the two isoforms, fine-tuning how much of each variant is made. The net effect is a subtle but reproducible modulation of downstream NF-κB activation and cytokine secretion profiles in monocytes and neutrophils — not an on/off switch, but a dial adjustment.

Because TLR8 is X-linked, the allele dosage differs between sexes in a fundamental way. Males have a single allele (either A or G), while females have two alleles and can be homozygous (AA or GG) or heterozygous (AG). The heterozygous state in females means they express both TLR8 isoform ratios simultaneously, potentially creating a more balanced signaling profile. Males, with only one copy, experience the full directional effect of whichever allele they carry. This X-linked dosage asymmetry appears to explain the consistent pattern of sex-specific findings seen across independent tuberculosis and HIV studies.

The Evidence

The tuberculosis associations are the best-replicated findings for this variant. A 2015 South African case-control study³³ A 2015 South African case-control study
Salie et al., 729 TB cases and 487 controls found that rs3764880 showed opposite effects by sex: females with the G allele were more susceptible to TB (OR=1.42, p=0.011), while males with the G allele were protected (OR=0.75, p=0.036). This sex-opposing pattern was replicated in a Moldavian cohort of 272 TB cases and 251 controls⁴⁴ a Moldavian cohort of 272 TB cases and 251 controls
Varzari et al. 2019, PMID 30529560, where males carrying the minor allele had notably lower TB risk (OR=0.44, p=0.0087). In a large Chinese Han cohort (584 cases and 608 controls, validated in a second independent sample)⁵⁵ a large Chinese Han cohort (584 cases and 608 controls, validated in a second independent sample)
Wang et al. 2018, PMID 30424735, the A allele was protective in males (OR=0.58, 95% CI 0.37–0.91), while the homozygous AA genotype actually increased pulmonary TB risk in females (OR=4.81) — a striking reversal. A meta-analysis of 29 studies covering 17,804 individuals confirmed that TLR8 rs3764880 A alleles were associated with overall tuberculosis susceptibility⁶⁶ TLR8 rs3764880 A alleles were associated with overall tuberculosis susceptibility
Sun et al. 2015, PMID 25877346, with the male-specific protective effect appearing in subgroup analyses.

For HIV, the G allele appears protective against disease progression. An 18-month cohort study of 782 HIV-positive adults and 550 controls⁷⁷ An 18-month cohort study of 782 HIV-positive adults and 550 controls
Oh et al. 2008, PMID 18605904 found that the A1G polymorphism was significantly protective against HIV disease progression, with laboratory evidence showing impaired NF-κB activation in G-allele carriers — a finding consistent with the reduced cytokine storm hypothesis. However, the X-linked complexity reasserts itself in early life: a perinatal HIV cohort of 368 Kenyan infants⁸⁸ a perinatal HIV cohort of 368 Kenyan infants
Beima-Sofie et al. 2013, PMID 24037211 found that female infants carrying the G allele had a 0.78 log₁₀ copies/ml higher peak viral load (p=0.0009), suggesting that at least in the context of neonatal HIV exposure, G allele expression in females may be disadvantageous.

The current evidence base is strong — multiple independent replication cohorts across diverse populations have confirmed the sex-specific tuberculosis associations, and the functional mechanism linking the variant to isoform ratio changes has been demonstrated in primary human cells. The overall picture, however, is complex enough that no simple "good allele / bad allele" framing applies.

Practical Implications

For men, the A allele (the reference, more common in most populations) is associated with lower TB risk in multiple independent studies, while the G allele may carry modest increased susceptibility. In male genotyping results (hemizygous — one copy only), the A call represents the protective state. For women, the relationship is inverted and dose-dependent: heterozygous AG women appear to have an intermediate or near-neutral risk profile, while homozygous AA women show paradoxically elevated TB risk in at least one large study. Homozygous GG women appear to carry the highest TB susceptibility in studies where female risk is elevated.

TB risk from this SNP is one factor among many. BCG vaccination status, TB exposure history, nutritional status, and overall immune competence dominate risk. This variant most relevantly informs awareness of susceptibility in endemic settings and the priority of maintaining BCG coverage.

Interactions

TLR8 signals through the same MyD88-dependent pathway as TIRAP and TLR4. The TIRAP rs8177374 (Ser180Leu)⁹⁹ rs8177374 (Ser180Leu) variant modulates how efficiently TIRAP bridges activated TLR receptors to MyD88 — the immediate downstream partner that TLR8 also recruits after pathogen RNA recognition. While TLR8 uses the MyD88-dependent pathway rather than the TIRAP-bridged TLR2/TLR4 cascade, both converge on NF-κB and cytokine production. Individuals carrying variants at both TIRAP and TLR8 may experience compounded modulation of mycobacterial immune responses.

TLR7 (rs179008), located adjacent to TLR8 on the X chromosome, is a closely related receptor that also recognizes single-stranded RNA and is in strong functional interaction with TLR8 for antiviral immunity. The two receptors share endosomal localization and compete for the same ligands.

Two adjacent genes on chromosome 5 occupy opposite ends of the same molecular story. GPX3¹¹ GPX3
Glutathione Peroxidase 3, a secreted antioxidant enzyme that neutralizes hydrogen peroxide in blood and tissues sits upstream on the forward strand. Downstream on the reverse strand lies TNIP1²² TNIP1
TNF Alpha-Induced Protein 3 Interacting Protein 1, encoding ABIN-1, the scaffolding partner required for A20-mediated NF-κB termination. The two genes are separated by roughly 100 kilobases but share a chromatin interaction network — regulatory variants in this region influence both genes simultaneously. rs3805435 sits in an intron of GPX3, but the haplotype it tags has been studied principally through its effects on ABIN-1 levels and NF-κB regulation in immune cells.

The Mechanism

ABIN-1, encoded by TNIP1, acts as a molecular scaffold that delivers A20 (encoded by TNFAIP3) to its ubiquitinated substrates within the NF-κB signaling complex. Without adequate ABIN-1, A20 cannot locate and edit the polyubiquitin chains on RIPK1, TRAF6, and NEMO that sustain NF-κB activation — the off-switch for the inflammatory cascade remains partly disconnected even when A20 protein is present.

Variants at the GPX3/TNIP1 locus affect TNIP1 expression in immune cells. Haplotypes carrying certain combinations across this region are associated with reduced ABIN-1 protein levels³³ reduced ABIN-1 protein levels
Bolin et al. 2012 showed two independent TNIP1 risk haplotypes in SLE cohorts produced lower TNIP1 mRNA and ABIN1 protein, consistent with hypomorphic expression, which blunts NF-κB termination after inflammatory stimuli. rs3805435 tags one component of the GPP-associated TNIP1 haplotype H4 identified by Han et al.; the C allele (which is considerably more common in East Asian populations, reaching ~42% frequency, versus ~8% in Europeans) is associated with maintained or enhanced regulatory capacity — resulting in lower GPP susceptibility in its carriers.

The GPX3/TNIP1 locus also has a chromatin-level regulatory structure in which variants at multiple positions interact to set net TNIP1 expression. Functional characterization of this region in ALS⁴⁴ Functional characterization of this region in ALS
Lall et al. 2022, Genome Medicine: eQTL and chromatin analyses of the GPX3/TNIP1 locus identified candidate regulatory SNPs affecting both GPX3 and TNIP1 expression across cell types found that the same chromatin architecture implicated in autoimmune risk also appears in neuroinflammatory disease — underscoring the pleiotropic nature of this locus.

The Evidence

The primary association evidence for rs3805435 comes from Han et al. 2016⁵⁵ Han et al. 2016
Han et al., Chin Med J 2016; 73 GPP patients, 67 PPP patients, 476 Chinese Han controls, which genotyped six TNIP1 SNPs in a Chinese Han cohort. The C allele (reported as G in that paper, which used reverse-strand notation for the TNIP1 coding strand) was significantly less frequent in GPP cases (34%) versus controls (46%), yielding a protective OR of 0.61 (95% CI 0.42–0.88, P=7.22×10⁻³). Conversely, the T allele (paper's A) is carried at significantly higher frequency among GPP cases.

The same study defined a four-SNP haplotype H4 — carrying rs3805435 alongside rs17728338 and other TNIP1 variants — with OR=4.16 (P=4.46×10⁻⁷) for GPP versus controls at 13.1% versus 3.4% frequency. This haplotype-level association is considerably stronger than the individual SNP signals, supporting the view that rs3805435 tags a regulatory haplotype rather than being the sole causal variant.

The evidence is categorized as moderate: the association is statistically significant and biologically plausible within the established TNIP1-A20-NF-κB framework, but it derives from a single cohort study in one ancestry group (Han Chinese). The C allele frequency difference between populations (European ~8% vs East Asian ~42%) means this variant primarily affects risk stratification within East Asian ancestry groups; its population-attributable fraction in Europeans is small.

Practical Actions

For TT homozygotes — the overwhelming majority globally (~83%) and approximately 34% of East Asians — the clinical implication is that this locus contributes to the TNIP1 haplotype H4 associated with elevated GPP risk. The actionable context is primarily through its interaction with rs17728338: individuals who are TT at rs3805435 AND carry the A risk allele at rs17728338 belong to the highest-risk GPP haplotype. The primary interventions for NF-κB dysregulation at the TNIP1 locus — vitamin D optimization and omega-3 supplementation — are addressed in the rs17728338 entry.

For CT heterozygotes and CC homozygotes, the presence of one or two protective C alleles is associated with reduced GPP susceptibility within the Han et al. haplotype framework. Carriers of CC are rare outside East Asian populations (<1% in Europeans) but represent approximately 17% of East Asians by Hardy-Weinberg calculation from the C allele frequency.

Interactions

rs3805435 and rs17728338 are part of the same TNIP1 haplotype block. The H4 risk haplotype defined in the Han et al. GPP study includes both SNPs; the compounded haplotype signal (OR=4.16) substantially exceeds either individual SNP's OR, consistent with the two variants jointly tagging the causal regulatory configuration at this locus. Carriers of both risk alleles (TT at rs3805435 and AA/AG at rs17728338) are candidates for a compound action representing the highest-risk TNIP1 haplotype for GPP and psoriatic inflammation.

The TNIP1 locus interacts functionally with rs610604 (TNFAIP3): ABIN-1 (TNIP1) scaffolds A20 (TNFAIP3) in the same NF-κB termination complex. Risk alleles at both loci impair complementary arms of the same braking system.

The melanocortin-3 receptor¹¹ melanocortin-3 receptor
A G-protein-coupled receptor expressed in the hypothalamus, limbic system, and peripheral tissues that responds to α-MSH and γ-MSH peptides derived from POMC serves a fundamentally different role from its better-known cousin MC4R. While MC4R primarily governs appetite and energy expenditure, MC3R acts as a feed-efficiency rheostat²² feed-efficiency rheostat
A rheostat is a variable resistor; here it controls how efficiently ingested calories are converted to fat rather than burned or used for lean tissue growth — determining where calories go once consumed. The Val44Ile variant (historically called V81I in older literature using a different transcript numbering) substitutes isoleucine for valine in the first transmembrane domain of the receptor, reducing receptor expression and setting a metabolic thermostat that favors fat storage over lean tissue accretion.

This SNP does not act alone. rs3827103 is in strong linkage disequilibrium³³ strong linkage disequilibrium
r² ≈ 0.65 in Europeans, near-complete LD in African ancestry populations, meaning the two alleles are inherited together far more often than chance would predict with rs3746619 (Thr6Lys), and functional studies consistently show that neither variant alone significantly impairs receptor signaling — the double mutant is required for measurable in vitro effects. Nonetheless, population studies examining Val44Ile independently show associations with lean body mass and puberty timing, and the A allele frequency varies dramatically by ancestry (8% in Europeans, 44% in Africans), making this variant clinically relevant across diverse populations.

The Mechanism

The Val-to-Ile substitution at position 44 (canonical NM_019888.3) sits within the first transmembrane helix of MC3R. When combined with the Thr6Lys change in the receptor's N-terminus (rs3746619), the double-mutant receptor shows approximately 60% fewer ligand binding sites⁴⁴ approximately 60% fewer ligand binding sites
Bmax 56.9 vs 137.7 pmol/L for wild-type in transfected HEK293 cells and substantially reduced intracellular cAMP generation in response to α-MSH — the primary MC3R ligand. Receptor membrane localization is preserved, suggesting impaired protein folding or accelerated degradation rather than trafficking failure.

At the metabolic level, reduced MC3R signaling shifts substrate oxidation⁵⁵ shifts substrate oxidation
Measured by respiratory exchange ratio under fasting conditions from lipids toward glucose, meaning the body preferentially burns carbohydrates and stores dietary fat. This altered nutrient partitioning⁶⁶ nutrient partitioning
Which macronutrients are burned for energy vs stored as fat or used to build lean tissue is distinct from simple hyperphagia. Knock-in mice carrying the human double mutant ate more per unit of fat-free mass but also showed markedly higher feed efficiency⁷⁷ markedly higher feed efficiency
Weight gained per calorie consumed, reflecting altered partitioning of ingested energy — gaining more fat per calorie than wild-type animals. Critically, pair-feeding experiments confirmed that altered partitioning, not just increased intake, drives the obesity phenotype.

A 2016 Nature Communications study revealed an additional mechanism: the double mutant biases mesenchymal stem cell differentiation⁸⁸ mesenchymal stem cell differentiation
Pluripotent stem cells in bone marrow that can become fat cells, bone, or muscle depending on signaling context toward adipocytes rather than osteoblasts. This explains why MC3R variant carriers show not only increased fat mass but also reduced bone mass and shorter stature — the same stem cell pool that would otherwise contribute to skeletal growth is redirected into fat tissue.

The Evidence

The most compelling human evidence comes from a 2005 case-control study⁹⁹ 2005 case-control study
Feng et al., 355 children aged 5-18, enriched for obesity, both African-American and Caucasian participants of 355 children in which 8.2% were double homozygous for both MC3R variants. These children had significantly higher BMI SD scores (5.3 ± 3.4 vs 2.4 ± 3.2 in wild-type), body fat percentage (43.6% vs 33.3%), plasma leptin (26.3 vs 11.4 mg/dL), and insulin resistance (HOMA-IR 5.4 vs 2.9), all significant at p < 0.0001. The double homozygous state was far more common in African-American children (15.8%) than Caucasian children (1.7%), reflecting allele frequency differences.

A 2018 meta-analysis¹⁰¹⁰ 2018 meta-analysis
Koya et al., 5 studies after screening 65 reports, pediatric populations synthesizing data from five pediatric studies found Val81Ile associated with 21.7% increased obesity risk per I allele. However, the evidence was complicated by high inter-study heterogeneity, and only homozygous T6K carriers showed statistically significant independent risk (OR 3.10, 95% CI: 1.29–7.43).

Beyond obesity, a 2023 study¹¹¹¹ 2023 study
Schwartz et al., 631 German children/adolescents, Sanger sequencing of MC3R coding region demonstrated that the Val44Ile minor allele independently associates with reduced total lean body mass (β = −59 kg, p = 0.004) and delayed puberty onset in both sexes (male: β = 0.038, p = 3.77 × 10⁻¹¹; female: β = 0.053, p = 8 × 10⁻¹¹). These associations with growth and reproductive timing suggest MC3R serves as a sensor linking nutritional status to anabolic signaling — when receptor activity is reduced, the body interprets itself as nutritionally deficient and delays energetically expensive processes like growth and reproduction.

The hypertension association¹²¹² hypertension association
rs3827103 Val81Ile: β = 4.9 mmHg systolic, p = 0.01 in 332 Kuwaiti subjects is mediated through elevated leptin: MC3R variants increase leptin levels, and leptin independently drives sympathetic nervous system activation that raises blood pressure. The AA haplotype of rs3746619–rs3827103 was significantly associated with systolic blood pressure (β = 5.03, p = 0.005).

In terms of weight loss response, a 760-person randomized trial¹³¹³ 760-person randomized trial
NUGENOB trial, hypo-energetic high- vs low-fat diets, 10-week intervention, obese European adults comparing high- and low-fat hypocaloric diets found no significant differential weight loss by MC3R genotype, suggesting that caloric restriction overcomes genotype-driven partitioning differences during active dieting.

Practical Actions

The practical implications of reduced MC3R activity center on the carbohydrate-fat tradeoff in substrate metabolism. Carriers who are homozygous for the A allele oxidize relatively more glucose and store more dietary fat — meaning dietary fat intake has outsized effects on body composition compared to non-carriers. Prioritizing protein to preserve lean mass is specifically relevant given the documented association with reduced lean body mass. Blood pressure monitoring is warranted given the leptin-mediated hypertension pathway.

Interactions

Val44Ile (rs3827103) and Thr6Lys (rs3746619) interact additively to produce the full receptor phenotype. Studies consistently show that neither variant alone significantly impairs MC3R cAMP signaling in vitro, but the double mutant shows ~60% reduced binding capacity and meaningfully decreased signal transduction. Individuals who are homozygous for the A allele at both SNPs carry the maximal metabolic risk; individuals heterozygous at both show intermediate effects. This interaction is the primary example in the MC3R literature of compound heterozygosity within a single gene producing a phenotype that neither variant achieves alone.

The leptin-hypertension pathway represents an additional interaction plane: rs3827103 carriers with elevated baseline leptin levels (which may also be influenced by FTO, LEP, and LEPR variants) face compounded risk for leptin-driven sympathetic activation and elevated blood pressure.